問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Recruiting

List

596Cases

2021-05-01 - 2024-09-19

Phase II/III

Completed
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40%

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD4831

Participate Sites
14Sites

Not yet recruiting1Sites

Recruiting11Sites

Terminated1Sites

Study ended1Sites

黃瑞仁
National Taiwan University Hospital

Division of Cardiovascular Diseases

2024-01-01 - 2027-12-31

Phase III

Active
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  • Condition/Disease

    Gastric Cancer /Gastroesophageal Junction Cancer

  • Test Drug

    AZD0901

Participate Sites
7Sites

Recruiting7Sites

2023-09-01 - 2029-12-31

Phase III

Active
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

  • Condition/Disease

    Metastatic Non-small Cell Lung Cancer

  • Test Drug

    VolrustomigKeytruda Injection

Participate Sites
13Sites

Recruiting13Sites

2023-06-01 - 2026-12-31

Phase I

Active
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Gastric Cancer 、Gastro-esophageal Junction Cancer 、Pancreatic Ductal Adenocarcinoma、 Esophageal Adenocarcinoma

  • Test Drug

    AZD5863

Participate Sites
3Sites

Recruiting3Sites

2023-01-30 - 2028-11-27

Phase II

Active
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    MEDI5752 AVASTIN LENVIMA AZD2936

Participate Sites
8Sites

Recruiting8Sites

2023-06-01 - 2026-12-31

Phase III

Active
A Phase III, Multicentre, Randomised, Double-blind, Chronic- dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    injection

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2024-08-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

  • Condition/Disease

    Atherosclerotic Cardiovascular Disease

  • Test Drug

    tablet

Participate Sites
8Sites

Recruiting8Sites

2025-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2028-12-31

Phase II

Active
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

  • Condition/Disease

    Asthma

  • Test Drug

    Tozorakimab

Participate Sites
8Sites

Recruiting8Sites

1 9 10 11 12 13 60
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB